Stocksigma LogoStocksigma Logo

Gland Pharma Q2FY27 Financial and Operational Performance Summary

Gland Pharma reported Q2FY27 consolidated revenue of ₹18,336 Mn, up 23% YoY, driven by 42% YoY growth in the US market (64% revenue share) and 30% YoY

Gland Pharma Q2FY27 Financial and Operational Performance Summary

Gland Pharma Ltd · Investor Presentation · 06 Nov 2026, 10:32 pm

Gland Pharma Q2FY27 Financial and Operational Performance Summary Gland Pharma reported Q2FY27 consolidated revenue of ₹18,336 Mn, up 23% YoY, driven by 42% YoY growth in the US market (64% revenue share) and 30% YoY growth in Europe. EBITDA surged 53% YoY to ₹4,804 Mn with margins expanding 500 bps to 26%, while PAT rose 58% YoY to ₹2,908 Mn. The company launched 4 molecules in the US, filed 11 ANDAs, and received 10 approvals. Cash and bank balances stood at ₹34,412 Mn with net cash of ₹32,216 Mn.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements